1. Thailand Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Mega Lifesciences Public Company Limited

Mega Lifesciences Public Company Limited

MEGA.BK
Mega Lifesciences Public Company LimitedTH flagStock Exchange of Thailand
37.00
THB
- -
- -
32.26BMarket Cap
Mega Lifesciences Public Company Limited
MEGA.BK
(Stock Exchange of Thailand)

Recent

price

37.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
6.65
8.19
9.42
8.93
9.18
10.18
11.09
11.77
12.78
14.44
16.21
17.99
17.99
17.6
16.23
16.48
Revenue per Share
- -
0.62
0.79
0.84
0.63
0.8
0.92
1.29
1.39
1.31
1.6
2.23
2.57
2.29
2.31
2.19
2.37
Basic EPS, GAAP
- -
0.26
-0.39
0.09
0.46
0.48
1.11
0.81
0.18
1.1
1.58
2.94
1.93
1.87
2.46
2.41
2.95
Free Cash Flow per Basic Share
- -
0.13
0.2
1.13
0.28
0.41
0.47
0.54
0.71
0.71
0.77
1.06
1.61
1.65
1.6
1.6
1.6
Dividend per Share
- -
1.89
2.49
2.2
2.24
2.63
3.07
3.82
4.51
5.06
5.86
7.03
8.05
8.68
9.4
10
10.66
Book Value per Share
- -
1.8
2.08
4.66
4.33
4.74
4.4
5.03
5.3
5.82
6.5
7.65
8.54
9.16
9.82
10.23
10.55
Tangible Book Value per Share
- -
730
728
747
865
865
865
865
865
871
872
872
872
872
872
872
871
Basic Weighted Avg Shares
- -
4,857
5,965
7,034
7,730
7,945
8,810
9,597
10,182
11,130
12,589
14,136
15,686
15,681
15,344
14,147
14,348
Sales/Revenue/Turnover
- -
11.39
10.95
10.29
8.2
8.67
11.49
14.13
13.14
12.6
13.4
15.15
17.09
18.52
21.96
20.52
21.1
Operating Margin (%)
- -
69
76
99
131
145
152
152
148
160
256
274
272
286
283
283
279
Depreciation Expense
- -
456
578
624
548
696
795
1,113
1,206
1,139
1,393
1,947
2,242
1,993
2,012
1,912
2,067
Net Income, GAAP
- -
18.99
17.05
17.61
14.15
15.97
14.77
14.31
14.39
12.32
14.44
14.76
13.67
11.9
14.44
20.47
22.04
Effective Tax Rate (%)
- -
9.39
9.69
8.87
7.09
8.76
9.02
11.59
11.84
10.23
11.06
13.77
14.29
12.71
13.12
13.51
14.4
Profit Margin (%)
543
933
1,079
2,678
2,329
3,068
2,536
3,104
2,683
3,072
3,358
4,448
5,052
5,563
6,312
6,256
6,555
Working Capital
26
5
347
212
137
84
7
- -
2
1
111
132
109
132
140
146
121
LT Debt
850
1,318
1,710
3,693
3,978
4,335
4,680
5,244
5,724
6,175
6,979
8,025
8,777
9,302
9,877
10,215
10,507
Total Equity
- -
25.02
21.2
15.39
11.62
11.86
16.29
20.4
17.97
17.52
19.16
22.16
25.54
26.59
28.26
20.99
20.91
Return on Invested Capital (%)
- -
25.67
23.04
23.12
21.85
25.69
25.76
31.76
28.47
23.55
26.34
32.17
32.53
26.48
24.78
21.63
22.18
Return on Capital (%)
- -
39.1
36.23
36.11
30.56
33.03
32.24
37.31
33.48
27.43
29.27
34.64
34.1
27.32
25.53
22.62
23.06
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
495
537
543
LT Borrowings
- -
- -
- -
LT Finance Leases
122
146
121
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
872
872
872
Market Capitalization
26,875
29,042
29,601

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
10,443
11,353
11,642
Cash, Cash Equivalents & STI
3,773
4,629
4,637
Accounts Receivable, Net
3,108
3,306
3,300
Inventories
3,103
3,038
3,259
Total Current Liabilities
4,540
5,096
5,088
Payables & Accruals
3,919
4,337
4,414
ST Debt
495
537
543
Deferred Revenue
- -
91
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9%
7.99%
3.43%
Free Cash Flow
65.42%
15.75%
-1.9%
Net Income, GAAP
11.92%
7.97%
-4.99%
Sales/Revenue/Turnover
6.16%
2.65%
-7.8%
Total Cash Common Dividend
15.98%
17.87%
0.03%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,733
3,954
4,001
3,657
15,344
2025
3,208
3,399
3,876
3,664
14,147
2026
3,408
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.59
0.44
- -
2.31
2025
0.52
0.45
0.57
- -
2.19
2026
0.69
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.8
0.8
- -
1.6
2025
- -
0.8
0.8
- -
1.6
2026
- -
- -
- -
- -
- -
Similar Companies
AstraZeneca Pharma India Limited (ASTRAZEN.NS)
The United Laboratories International Holdings Limited (ULIHF)
Nutranomics, Inc. (NNRX)
Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ)
Boiron S.A. (BOI.PA)
Golden Developing Solutions, Inc. (DVLP)
Business
Mega Lifesciences Public Company Limited Mega Lifesciences Public Company Limited manufactures, markets, sells and distributes pharmaceutical, nutraceutical and fast-moving consumer goods products worldwide. The company offers a broad portfolio of health food supplements, prescription pharmaceutical products, over-the-counter medications, herbal products, vitamins, probiotics and medical and sports nutrition; its branded offerings under MEGA We Care and MAXXCARE include solutions for allergies, blood circulation and memory, bone and joint health, liver and digestive care, diabetes management, eye care, heart and skin care, pain relief, sleep and well-being, cough and colds, women's and men's health, kids' care, hair care and general wellness. Mega Lifesciences operates through three segments—Brands, Distribution and Original Equipment Manufacture (OEM)—and provides logistical and marketing services for third-party goods, social enterprise initiatives and wellness centers; it manufactures at facilities in Thailand and Australia accredited by international good manufacturing practice authorities. Founded in 1982 and headquartered in Bangkok, Thailand, the company exports to Asia-Pacific, Middle East, Africa, CIS countries, Latin America and Europe, serving healthcare practitioners, consumers and institutional customers across the health and wellness industry value chain. Recent developments include the release of its reviewed financial statements and management discussion for the third quarter of 2025 on November 13, alongside an ongoing commitment to sustainability as an ESG-listed company in Thailand and progression toward inclusion in relevant indices.